Sigma Healthcare (SIG) investor relations material

Opening remarks and agenda

• Agenda covered the Chairman and CEO addresses, financial statements and reports, the remuneration report, director re-elections, and executive remuneration arrangements.

• Opening remarks highlighted scale, capability, defensive earnings and long-term growth pathways; executives were available to speak with shareholders afterward.

• Meeting used a hybrid format for in-person and online participation.

Financial performance review

• FY26 revenue was $10.8bn, up 15.5%; normalised EBIT was $605m, up 20.6%, and NPAT grew 22.3%.

• First full year post-merger; earnings grew faster than revenue as scale improved efficiency.

• Net debt was $663m, or 0.57x normalised EBITDA.

• Sales rose 12.1%; vitamins and supplements were soft amid consumer spending adjustments, while beauty, healthcare and GLP-1 categories performed more strongly.

Board and executive committee updates

• Michael Sammells was Chairman and Chair of the Related Party Independent Board Committee; Vikesh Ramsunder was Managing Director and CEO.

• Michael Sammells, Mario Verrocchi and Damien Gance offered themselves for re-election; Sammells cited healthcare, finance, M&A and governance experience, while Verrocchi intended to remain through full integration.

• Gance highlighted his work with franchisees and state and territory pharmacy boards, and his focus on supporting pharmacists and franchise partners.

• The Board was described as relatively new following the merger and Sigma EGM shareholder vote; succession planning was in place.

• Committee chairs included Chris Roberts AO for Risk, Compliance and Sustainability; Annette Carey for Nomination and Remuneration; and Neville Mitchell for Audit.